

## SCIENTIFIC AND TECHNOLOGICAL PROFILE OF THE GROUP

**RICORS Code**  
**RD21/0012/0017**

<b>Thematic area:</b>	PRIMARY CARE, CHRONICITY AND HEALTH PROMOTION
<b>Programme name:</b>	PRIMARY CARE INTERVENTIONS TO PREVENT MATERNAL AND CHILD CHRONIC DISEASES OF PERINATAL AND DEVELOPMENTAL ORIGIN
<b>Group leader:</b>	ÓSCAR GARCÍA-ALGAR
<b>Applicant Institution:</b>	FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA (FCRB)
<b>Working Institution:</b>	HOSPITAL CLÍNIC BARCELONA
<b>PI Work Institution:</b>	HOSPITAL CLÍNIC BARCELONA

### Participants

Researcher	Family Name (s)	First Name (s)	Work Institution	Position
1	Garcia-Algar	Oscar	Hospital Clinic Barcelona	Contracted
2	Alsina Casanova	Miquel	Hospital Clinic Barcelona	Contracted
3	Andreu Fernandez	Vicente	Fundacio Clinic Recerca Biomedica	Contracted
4	Astals Vizcaino	Marta	Fundacio Clinic Recerca Biomedica	Contracted
5	Sebastiani	Giorgia	Hospital Clinic Barcelona	Contracted
6	Llupia Garcia	Anna	Hospital Clinic Barcelona	Contracted
7	Perez Martinez	Esther	Centro de Salud Galapagar, Servicio Madrileño de Salud (SERMAS)	Contracted
8	Borras Novell	Cristina	Hospital Clinic Barcelona	Contracted
9	Aldecoa Bilbao	Victoria	Hospital Clinic Barcelona	Contracted
10	Iriondo Sanz	Marti	Hospital Sant Joan de Deu Barcelona	Contracted

## PUBLICATIONS

Up to twenty selected publications related to the RICORS's Thematic Area (published in the last five years)

1. Maya S, Ramis SM, Astals M, García-Algar Ó. Perfil neurocognitivo y conductual del trastorno del espectro alcohólico fetal [Neurocognitive and behavioral profile of fetal alcohol spectrum disorder]. *An Pediatr (Barc)*. 2021 Mar 18;S1695-4033(20)30538-5. PMID: 33745838. IF 1.313
2. Gómez-Roig MD, Pascal R, Cahuana MJ, García-Algar O, Sebastiani G, Andreu-Fernández V, et al. Environmental Exposure during Pregnancy: Influence on Prenatal Development and Early Life: A Comprehensive Review. *Fetal Diagn Ther*. 2021 Mar 18;1-13. PMID: 33735860. IF 2.095
3. Navarro E, Almeida L, Sebastiani G, Serra M, García-Algar Ó, Andreu V. Effects of Microbiota Imbalance in Anxiety and Eating Disorders: Probiotics as Novel Therapeutic Approaches. *Int J Mol Sci*. 2021 Feb 26;22(5):2351. PMID: 33652962. IF 4.556
4. Colom J, Segura L, Bastons A, Astals M, Andreu V, Barcons N, et al. Prevalence of Fetal Alcohol Spectrum Disorders (FASD) among Children Adopted from Eastern European Countries: Russia and Ukraine. *Int J Environ Res Public Health*. 2021 Feb 3;18(4):1388. PMID: 33546212. IF 2.849
5. Sebastiani G, Andreu V, Herranz A, Aldecoa V, Miracle X, Meler E, et al. Eating Disorders During Gestation: Implications for Mother's Health, Fetal Outcomes, and Epigenetic Changes. *Front Pediatr*. 2020 Sep 17;8:587. PMID: 33042925. IF 2.634
6. Borràs C, Herranz A, Aldecoa V, Feixas G, Balcells C, Sánchez E, et al. Infrared analyzers for the measurement of breastmilk macronutrient content in the clinical setting. *Expert Rev Mol Diagn*. 2020 Sep;20(9):867-887. PMID: 32876510. IF 4.096
7. Navarro E, Sebastiani G, Sailer S, Toledano LA, Serra M, García-Algar Ó, et al. Probiotic Supplementation During the Perinatal and Infant Period: Effects on Gut Dysbiosis and Disease. *Nutrients*. 2020 Jul 27;12(8):2243. PMID: 32727119. IF 4.546
8. Pichini S, Busardò FP, Garcia-Algar O. Only Total Abstinence From Alcohol Consumption During Pregnancy Guarantees Absolute Absence of Any Deleterious Effect in the Fetus and Child. *J Stud Alcohol Drugs*. 2020 Mar;81(2):220-221. PMID: 32359052. IF 2.448
9. Mesa MD, Loureiro B, Iglesia I, Fernandez S, Llurba E, García Algar O, et al. The Evolving Microbiome from Pregnancy to Early Infancy: A Comprehensive Review. *Nutrients*. 2020 Jan 2;12(1):133. PMID: 31906588. IF 4.546
10. Mendoza R, Morales-Marente E, Palacios MS, Rodríguez-Reinado C, Corrales-Gutiérrez I, García-Algar Ó. Health advice on alcohol consumption in pregnant women in Seville (Spain). *Gac Sanit*. 2020 Sep-Oct;34(5):449-458. PMID: 30733046. IF 1.564
11. Sebastiani G, Herranz A, Borràs C, Alsina M, Aldecoa V, Andreu V, et al. The Effects of Vegetarian and Vegan Diet during Pregnancy on the Health of Mothers and Offspring. *Nutrients*. 2019 Mar 6;11(3):557. PMID: 30845641. IF 4.54612.
12. Sebastiani G, Borràs C, Casanova MA, Pascual M, Ferrero S, Gómez MD, et al. The Effects of Alcohol and Drugs of Abuse on Maternal Nutritional Profile during Pregnancy. *Nutrients*. 2018 Aug 2;10

(8):1008. PMID: 30072661. IF 4.546

13. Cortes L, Almeida L, Sabra S, Muniesa M, Busardo FP, Garcia-Algar O, et al. Maternal Hair and Neonatal Meconium to Assess Gestational Consumption and Prenatal Exposure to Drugs of Abuse and Psychoactive Drugs. *Curr Pharm Biotechnol*. 2018;19(2):136-143. PMID: 29621962. IF 2.097
14. Bastons A, Astals M, Andreu V, Navarro E, Garcia-Algar O. Postnatal nutritional treatment of neurocognitive deficits in fetal alcohol spectrum disorder. *Biochem Cell Biol*. 2018 Apr;96(2):213-221. PMID: 29091739. IF 2.460
15. Falcón M, Navarro J, García-Rodríguez RM, Nova D, González MD, Mercadal M, et al. Perceived barriers to implementing screening and brief intervention for alcohol consumption by adolescents in hospital emergency department in Spain. *Adicciones*. 2018 Jul 12;30(3):189-196. PMID: 28749525. IF 3.702
16. Gomez MD, Marchei E, Sabra S, Busardò FP, Mastrobattista L, Pichini S, et al. Maternal hair testing to disclose self-misreporting in drinking and smoking behavior during pregnancy. *Alcohol*. 2018 Mar;67:1-6. PMID: 29289821. IF 2.006
17. Chiandetti A, Hernandez G, Mercadal M, Alvarez A, Andreu V, Navarro E, et al. Prevalence of prenatal exposure to substances of abuse: questionnaire versus biomarkers. *Reprod Health*. 2017 Oct 25;14(1):137. PMID: 29070078. IF 2.177
18. Kyriakou C, Pellegrini M, García-Algar O, Marinelli E, Zaami S. Recent Trends in Analytical Methods to Determine New Psychoactive Substances in Hair. *Curr Neuropharmacol*. 2017;15(5):663-681. PMID: 27834146. IF 4.668
19. Escuder D, Garcia-Algar Ó, Joya X, Marchei E, Pichini S, et al. Breast Milk and Hair Testing to Detect Illegal Drugs, Nicotine, and Caffeine in Donors to a Human Milk Bank. *J Hum Lact*. 2016 Aug;32(3):542-5. PMID: 27197576. IF 2.205
20. Joya X, Mazarico E, Ramis J, Pacifici R, Salat J, Mortali C, et al. Segmental hair analysis to assess effectiveness of single-session motivational intervention to stop ethanol use during pregnancy. *Drug Alcohol Depend*. 2016 Jan 1;158:45-51. PMID: 26589976. IF 3.951

RICORS Code RD21/0012/0017

## INTERNATIONAL AND NATIONAL RESEARCH PROJECTS

(Funded in the last five years)

1. PI: Oscar Garcia-Algar. 98.010€. Estudio epigenómico, metabólico y metagenómico de una cohorte de niños con Síndrome Alcohólico Fetal: modelo diagnóstico y nuevas dianas terapéuticas (PI19/01853)  
Funding entity: FIS (Fondo de Investigaciones Sanitarias), ISCIII  
Dates: 2020-2022
2. PI: Oscar Garcia-Algar. 82.400€. Contratos predoctorales de formación en investigación (PFIS) (FI20/00206)  
Funding entity: FIS (Fondo de Investigaciones Sanitarias), ISCIII  
Dates: 2021-2023
3. PI: Oscar Garcia-Algar. 168.305,50€. Red Salud Materno Infantil y Desarrollo. (RD16/0022/0002)  
Funding entity: ISCIII  
Dates: 2017-2021
4. PI: Oscar Garcia-Algar. 18.000€. Informe sobre alcohol, embarazo y trastorno del espectro alcohólico fetal (TEAF)  
Funding entity: Ministerio de Sanidad, Consumo y Bienestar Social  
Dates: 2020-2021
5. PI: Antoni Gual. Collaborator researcher: Oscar Garcia-Algar. 999.350€. EU dimension of alcohol related harm - piloting brief interventions to reduce the risk of FAS/FASD. (3781)  
Funding entity: CHAFEA/2018/Health/10. European Commission  
Dates: 2018-2021
6. PI: Oscar Garcia-Algar. 86.515€. Alteraciones epigenéticas generadas por exposición prenatal al alcohol en pacientes con SAF (síndrome alcohol fetal). Antioxidante epigallocatequina (EGCG) como herramienta terapéutica (16/00566)  
Funding entity: FIS (Fondo de Investigaciones Sanitarias), ISCIII  
Dates: 01/01/2017 - 31/12/2019
7. PI: Oscar Garcia-Algar. 48.097,50€. Nombre del proyecto: Efectos clínicos de la exposición prenatal al alcohol: seguimiento de una cohorte (PI13/001135)  
Funding entity: FIS (Fondo de Investigaciones Sanitarias), ISCIII  
Dates: 01/01/2014 - 31/12/2016

**RICORS Code RD21/0012/0017**

## **PATENTS**

**(Granted and licensed patents in the last five years. Include also licensed know-how)**

Licensed know-how

Oscar Garcia-Algar. Technology license agreement: Psicoterapia VR (B01764018) and VisualFASD (licensee) and Hospital Clinic Barcelona and IDIBAPS (licensors). Oscar Garcia-Algar (CSO). January 28, 2021.

## RICORS Call: Scientific and Technological Profile of the Participating Groups

**Aim:** describe the major contributions of the different participating groups in terms of papers, funding and patents.

**!** The structure of this template has been designed to ensure that the important aspects of your scientific and technological profile are presented in a way that will enable experts to make an effective assessment against the evaluation criteria.

**!** The font type and size recommended is Arial 9 points. Please respect the page limits and do not take it as a target either! It is in your interest to keep your text as concise as possible, since experts rarely view unnecessarily long documents in a positive light.

### Section 1. List of Participating Groups. PI participants.

**!** Remember

PI's Family Name | PI's First name(s) | PI's Work Institution | Position \*

\*Position: officer, statutory staff; contracted; fellow

### Section 2. Papers

**Indicate:** Authors; Title; Journal; PMID; Type of paper; Publication year; Impact Factor (JCR Thomson Reuters) and times cited.

### Section 3. International and National Research Projects

**!** Do not include regional or privately funded projects.

**Indicate:** Project ID; Name of the PI; Title; Funding Agency; Amount of Funding & Duration.

### Section 4. Patents

**Indicate:** Applicant; Title; Inventors; Patent Office; Date of application number; Date of grant and Entity-Organization Exploiting the Patent.